BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patie false
áéåìééï àø à÷ñ áò"î 2 380
BIOLINE RX LTD
Corporation no: 513398750 8688
Israel Securities Authority   Tel Aviv Stock Exchange   C002 ( Public )   Reported via MAGNA: 18/02/2024
  www.isa.gov.il     www.tase.co.il       Reference: 2024-02-014494 Time of broadcast: 10:59 10:59
Immediate Report
Regulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000


The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report on

FORM_6-K_16-Feb-2024_isa.pdf
References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
       
Stock Exchange/Market: NASDAQ CM Date of revision of form structure: 31/12/2023
Address: HaMa'ayan 2 , Modi'in 7177871   , Israel Tel: 08-6429100 , Fax: 08-6429101
E-mail address: info@BioLineRx.com   Company site: www.biolinerx.com

Previous names of reporting entity:

Name of the Signatory: Serlin Philip Adam Position of Signatory in the reporting corporation: Chief Executive Officer Name of Employer Company:
Address: HaMa'ayan 2 , Modi'in 7177871 Telephone: 08-6429100 Facsimile: 08-6429101 E-mail: phils@biolinerx.com 1
Israel